Table 6

Numbers (percentages) of patient consultations over a one year period for which an integrated care pathway was completed (by condition and clinical genetics centre)

Centre 1 Centre 2 Centre 3 Centre 4 Total
Tuberous sclerosis21/23  (91%)5/9  (55%)0/36/9  (67%)32/44  (73%)
Marfan syndrome29/39 (74%)5/10 (50%)20/43  (46%)21/41 (51%)75/133 (56%)
Myotonic dystrophy12/15 (80%)12/15 (80%)2/4 (50%)5/41 (12%)31/75 (41%)
Neurofibromatosis type 134/43 (79%)31/65 (48%)17/27 (63%)10/20 (50%)92/155 (59%)
Total96/120 (80%)53/99 (53%)39/77 (51%)42/111 (38%)230/407 (57%)